ISLAMABAD: The Ministry of National Health Services, Regulations and Coordination Monday continued its action against pharmaceutical companies on increasing rates of medicines against the approved prices of the federal government.
According to an official of the ministry, the government had decided to take strict action against unauthorized increase in prices of some medicines by pharmaceutical companies.
He said pharma industry would not be allowed to increase prices of their drugs over and above the approved maximum retail prices (MRPs).
He said action was being taken on complaints that pharmaceutical companies had increased prices of their drugs over and above the maximum retail price (MRPs) approved by the federal government.
The official said the ministry had also directed Drug Regulatory Authority of Pakistan (DRAP) to conduct market surveys for determination of overpricing.
DRAP had been advised to monitor MRPs in the market to ensure that the same were not higher than the notified prices.
He said the authority had also directed that in case of stocks available in the retail shops or manufactured or imported prior to issuance of SROs must be sold at previous MRPs printed on the label in the manner prescribed by the Drugs (Labeling and Packing) Rules, 1986 while stickers or cuttings were not allowed.
The DRAP had allowed only nine percent MRPs increase in hardship category and only 15 percent MRPs increase of medicines determined under the Drug Pricing Policy, 2018 for drugs other than those specified in clause (a), the official added.
He added that the federal government had issued clear directions to DRAP to take strict action against pharmaceutical companies selling medicines on exorbitant prices.
He said the authority had recommended registering of cases on overpriced medicines under the Drug Act, besides imposing heavy fines with recovery of overpriced amount.
He said cases would be registered against the companies on overpricing for recovery of the overpriced amount.
Sindh health minister appeals to parents not to refuse OPV teams
KARACHI: Sindh Minister for Health Dr. Azra Pechuho here on Monday urged parents not to refuse the vaccinators visiting their homes for administration of oral polio vaccine (OPV) even if their children may have been regularly covered under routine immunisation.
Talking to journalists following the inaugural of the national OPV campaign at the Sindh Emergency Operation Centre for Polio, she said the additional drops received by their kids under OPV hold no hazard but simply boost immunity of the recipients.
“The exercise is meant to provide blanket cover to all children against the virus that persists in our environment,” said the health minister who is also a senior doctor.
Acknowledging that a reluctance has been registered among many of the affluent families in easing access of their under-five children to the mobile teams of vaccinators, engaged in door-to-door oral polio immunisation campaign, she said the elitist mindset has to be done away with.
She urged the media, both print and electronic, to make people realise that OPV being administered at the clinics of renowned pediatricians or that of government-run dispensaries or by authorised mobile teams are of same quality arranged by the government through Bill and Melinda Gates Foundation.
Countrywide anti-polio campaign commences
ISLAMABAD: A countrywide campaign to administer anti-polio drops to children under five years of age starts on Monday.
National Coordinator Polio Eradication Programme, Dr Rana Safdar said the anti-polio drive will target 39 million children in all four provinces, Azad Kashmir and Gilgit-Baltistan.
He urged the people to cooperate with polio teams to administer drops to their children against this crippling disease.
FDA approves first medical device to treat child inattention
WASHINGTON: The U.S. Food and Drug Administration (FDA) approved this week the first medical device to treat attention deficit hyperactivity disorder (ADHD) for children.
The device called the Monarch external Trigeminal Nerve Stimulation (eTNS) System is the first non-drug treatment for ADHD authorized for marketing by the FDA.
The prescription-only device is indicated for patients ages 7 to 12 years old who are not taking ADHD medication.
“This new device offers a safe, non-drug option for treatment of ADHD in pediatric patients through the use of mild nerve stimulation, a first of its kind,” said Carlos Pena, director of the Division of Neurological and Physical Medicine Devices in the FDA’s Center for Devices and Radiological Health.
ADHD is a common disorder that begins in childhood. ADHD patients have difficulty in staying focused and paying attention.
The cell-phone sized device generates a low-level electrical pulse and connects via a wire to a small patch that adheres to a patient’s forehead, just above the eyebrows, according to FDA.
The device delivers the low-level electrical stimulation to the branches of the trigeminal nerve, sending therapeutic signals to the parts of the brain thought to be involved in ADHD.
Brain imaging showed that eTNS increases activity in the brain regions that are known to be important in regulating attention, emotion and behavior, but the exact mechanism of eTNS is not yet known.
The stimulation feels like a tingling sensation on the skin, and the device should be used in the home under the supervision of a caregiver during periods of sleep. Clinical trials suggest that a response to eTNS may take up to four weeks to become evident.